Bicara Therapeutics Inc.
BCAX
$26.87
$0.532.01%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 56.69% | 5.60% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 46.50% | 1.10% | |||
| Operating Income | -46.50% | -1.10% | |||
| Income Before Tax | -50.43% | -2.87% | |||
| Income Tax Expenses | -1.89% | 32.50% | |||
| Earnings from Continuing Operations | -50.35% | -2.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -50.35% | -2.91% | |||
| EBIT | -46.50% | -1.10% | |||
| EBITDA | -46.54% | -1.05% | |||
| EPS Basic | -36.55% | -1.83% | |||
| Normalized Basic EPS | -36.63% | -1.78% | |||
| EPS Diluted | -36.55% | -1.83% | |||
| Normalized Diluted EPS | -36.63% | -1.78% | |||
| Average Basic Shares Outstanding | 10.11% | 1.06% | |||
| Average Diluted Shares Outstanding | 10.11% | 1.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||